Accelerate Diagnostics, Inc.

AXDXNASDAQHealthcare

$0.03

+$0.00(+0.00%)

Market Cap$859918

P/E Ratio—

52W High$2.09

52W Low$0.01

Avg Volume1.9M

Open$0.08

Beta0.22

Free Cash Flow Financials Revenue

Accelerate Diagnostics, Inc. (AXDX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AXDX · free cash flow · updated Jun 9, 2026

Core FCF metrics

AXDX · FCF · TTM · margin & CAGR

Free cash flow was −$24.7M for FY2024 (fiscal year ending 2024-12-31), up 40.1% year-over-year The FCF margin was -211.2%.

FY2024 Free Cash Flow−$24.7M▲ +40.1% YoY

Trailing 12M (TTM)−$24.7Mtrailing 4 quarters sum

FCF Margin-211.2%−$24.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AXDX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2024Latest−$24.2M(1M)−$24.7M▲ +40.1%-211.2%

FY2023−$40.2M(1M)−$41.2M▲ +16.3%-341.9%

FY2022−$48.7M(1M)−$49.3M▼ 2.8%-386.5%

FY2021−$47.3M(1M)−$47.9M▲ +7.4%-406.8%

FY2020−$50.4M(1M)−$51.8M▲ +20.5%-463.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AXDX · P/FCF · FCF yield · FCF per share

Accelerate Diagnostics, Inc. (AXDX) reported negative free cash flow of −$0.02B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2024 · 2024-12-31

Cash flow statement summary

AXDX · cash flow statement · operating / investing / financing

For FY2024, Accelerate Diagnostics, Inc. generated −$24.2M in operating cash flow and spent 1M in capital expenditures, yielding −$24.7M in free cash flow.

Operating Activities

−$24.2M

Cash from core business operations

2024-12-31

Investing Activities

−$0.5M

CapEx, acquisitions & investments

2024-12-31

Financing Activities

+$27.1M

Buybacks, dividends & debt

2024-12-31

FCF FormulaOperating CF (−$24.2M) − |CapEx| (1M) = FCF (−$24.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AXDX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Accelerate Diagnostics, Inc.YOU

AXDX

−$24.7M+40.1%-211.2%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Accelerate Diagnostics, Inc. (AXDX) reported free cash flow of −$24.7M for FY2024 (fiscal year ending 2024-12-31), up 40.1% year-over-year. The FCF margin was -211.2%.

Based on available data, Accelerate Diagnostics, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $373,145 in FY2011.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AXDX free cash flow · 8 questions

Accelerate Diagnostics, Inc. free cash flow was −$24.7M for FY2024, up 40.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$24.7M.

AXDX free cash flowAXDX FCFAXDX FCF 2024AXDX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Accelerate Diagnostics, Inc. · Accelerate Diagnostics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026